IDEAS home Printed from https://ideas.repec.org/f/pma2333.html
   My authors  Follow this author

James Mason

Personal Details

First Name:James
Middle Name:
Last Name:Mason
Suffix:
RePEc Short-ID:pma2333
[This author has chosen not to make the email address public]
http://scholar.google.co.uk/citations?user=KHN7qoQAAAAJ&hl=en

Affiliation

University of Warwick, Warwick Medical School

http://www2.warwick.ac.uk/fac/med/
Coventry

Research output

as
Jump to: Working papers Articles

Working papers

  1. James Mason & Anne Mason & Michael Cork, 2002. "Topical preparations for the treatment of psoriasis in primary care: a systematic review," Working Papers 041cheop, Centre for Health Economics, University of York.
  2. Anne Mason & James Mason, 2002. "Optometrist prescribing of therapeutic agents: economic implications for the UK," Working Papers 043cheop, Centre for Health Economics, University of York.
  3. Nick Freemantle & John Wood & James Mason, 1999. "Evaluating change in professional behaviour: issues in design and analysis," Working Papers 171chedp, Centre for Health Economics, University of York.
  4. James Mason & Martin Eccles & Nick Freemantle & Mike Drummond, 1998. "NICEly does it: economic analysis within evidence-based clinical practice guidelines," Working Papers 164chedp, Centre for Health Economics, University of York.
  5. James Mason & Mike Drummond, 1995. "The DH register of cost-effectiveness studies: a review of study content and quality," Working Papers 128chedp, Centre for Health Economics, University of York.
  6. James Mason & Mike Drummond, 1995. "Screening for diabetic retinopathy by optometrists: effectiveness and cost-effectiveness," Working Papers 137chedp, Centre for Health Economics, University of York.

Articles

  1. Simon Bullock & James Mason & Alice Larkin, 2022. "The urgent case for stronger climate targets for international shipping," Climate Policy, Taylor & Francis Journals, vol. 22(3), pages 301-309, March.
  2. Felix Achana & Daniel Gallacher & Raymond Oppong & Sungwook Kim & Stavros Petrou & James Mason & Michael Crowther, 2021. "Multivariate Generalized Linear Mixed-Effects Models for the Analysis of Clinical Trial–Based Cost-Effectiveness Data," Medical Decision Making, , vol. 41(6), pages 667-684, August.
  3. Hema Mistry & Chidozie Nduka & Martin Connock & Jill Colquitt & Theodoros Mantopoulos & Emma Loveman & Renata Walewska & James Mason, 2019. "Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 37(6), pages 869-869, June.
  4. Hema Mistry & Chidozie Nduka & Martin Connock & Jill Colquitt & Theodoros Mantopoulos & Emma Loveman & Renata Walewska & James Mason, 2018. "Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 36(4), pages 399-406, April.
  5. Karoline Freeman & Alexander Tsertsvadze & Sian Taylor-Phillips & Noel McCarthy & Hema Mistry & Rohini Manuel & James Mason, 2017. "Agreement between gastrointestinal panel testing and standard microbiology methods for detecting pathogens in suspected infectious gastroenteritis: Test evaluation and meta-analysis in the absence of ," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-16, March.
  6. Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou, 2017. "Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Sys," PharmacoEconomics, Springer, vol. 35(5), pages 501-515, May.
  7. James M Mason & Kim S Thomas & Angela M Crook & Katharine A Foster & Joanne R Chalmers & Andrew J Nunn & Hywel C Williams, 2014. "Prophylactic Antibiotics to Prevent Cellulitis of the Leg: Economic Analysis of the PATCH I & II Trials," PLOS ONE, Public Library of Science, vol. 9(2), pages 1-7, February.
  8. Wood, Victoria J. & Curtis, Sarah E. & Gesler, Wil & Spencer, Ian H. & Close, Helen J. & Mason, James & Reilly, Joe G., 2013. "Creating ‘therapeutic landscapes’ for mental health carers in inpatient settings: A dynamic perspective on permeability and inclusivity," Social Science & Medicine, Elsevier, vol. 91(C), pages 122-129.
  9. Curtis, Sarah & Gesler, Wilbert & Wood, Victoria & Spencer, Ian & Mason, James & Close, Helen & Reilly, Joseph, 2013. "Compassionate containment? Balancing technical safety and therapy in the design of psychiatric wards," Social Science & Medicine, Elsevier, vol. 97(C), pages 201-209.
  10. Wood, Victoria J. & Curtis, Sarah E. & Gesler, Wil & Spencer, Ian H. & Close, Helen J. & Mason, James M. & Reilly, Joe G., 2013. "Spaces for smoking in a psychiatric hospital: Social capital, resistance to control, and significance for ‘therapeutic landscapes’," Social Science & Medicine, Elsevier, vol. 97(C), pages 104-111.
  11. Mason, Anne & Mason, James, 2002. "Optometrist prescribing of therapeutic agents: findings of the AESOP survey," Health Policy, Elsevier, vol. 60(2), pages 185-197, May.
  12. Nick Freemantle & James Mason, 2000. "The Importance of Achieving Additional Drug Benefits at a Reasonable Cost," PharmacoEconomics, Springer, vol. 17(4), pages 319-324, April.
  13. Mason, James & Eccles, Martin & Freemantle, Nick & Drummond, Michael, 1999. "A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines," Health Policy, Elsevier, vol. 47(1), pages 37-52, April.
  14. Mason, James & Drummond, Michael, 1997. "Biotechnology: a special case for health technology assessment?," Health Policy, Elsevier, vol. 41(1), pages 73-81, July.
  15. James Mason, 1996. "Student corner," Health Economics, John Wiley & Sons, Ltd., vol. 5(4), pages 375-379, July.
  16. James Mason & Michael Drummond, 1995. "Reporting guidelines for economic studies," Health Economics, John Wiley & Sons, Ltd., vol. 4(2), pages 85-94, March.
  17. Drummond, Michael & Mason, James & Torrance, George, 1995. "Cost-effectiveness league tables: think of the fans," Health Policy, Elsevier, vol. 31(3), pages 231-238, March.
  18. Drummond, Michael & Torrance, George & Mason, James, 1993. "Cost-effectiveness league tables: More harm than good?," Social Science & Medicine, Elsevier, vol. 37(1), pages 33-40, July.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Anne Mason & James Mason, 2002. "Optometrist prescribing of therapeutic agents: economic implications for the UK," Working Papers 043cheop, Centre for Health Economics, University of York.

    Cited by:

    1. Mason, Anne & Mason, James, 2002. "Optometrist prescribing of therapeutic agents: findings of the AESOP survey," Health Policy, Elsevier, vol. 60(2), pages 185-197, May.

  2. James Mason & Mike Drummond, 1995. "The DH register of cost-effectiveness studies: a review of study content and quality," Working Papers 128chedp, Centre for Health Economics, University of York.

    Cited by:

    1. Mason, James & Eccles, Martin & Freemantle, Nick & Drummond, Michael, 1999. "A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines," Health Policy, Elsevier, vol. 47(1), pages 37-52, April.
    2. Clive Pritchard, 1998. "Trends in Economic Evaluation," Briefing 000444, Office of Health Economics.

Articles

  1. Simon Bullock & James Mason & Alice Larkin, 2022. "The urgent case for stronger climate targets for international shipping," Climate Policy, Taylor & Francis Journals, vol. 22(3), pages 301-309, March.

    Cited by:

    1. Fredrik von Malmborg, 2024. "Tapping the Conversation on the Meaning of Decarbonization: Discourses and Discursive Agency in EU Politics on Low-Carbon Fuels for Maritime Shipping," Sustainability, MDPI, vol. 16(13), pages 1-36, June.
    2. Natalia Wagner, 2023. "Inventive Activity for Climate Change Mitigation: An Insight into the Maritime Industry," Energies, MDPI, vol. 16(21), pages 1-23, November.

  2. Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou, 2017. "Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Sys," PharmacoEconomics, Springer, vol. 35(5), pages 501-515, May.

    Cited by:

    1. Iftekhar Khan & Mandy Maredza & Melina Dritsaki & Dipesh Mistry & Ranjit Lall & Sarah E. Lamb & Keith Couper & Simon Gates & Gavin D. Perkins & Stavros Petrou, 2020. "Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study," PharmacoEconomics - Open, Springer, vol. 4(4), pages 697-710, December.

  3. Wood, Victoria J. & Curtis, Sarah E. & Gesler, Wil & Spencer, Ian H. & Close, Helen J. & Mason, James & Reilly, Joe G., 2013. "Creating ‘therapeutic landscapes’ for mental health carers in inpatient settings: A dynamic perspective on permeability and inclusivity," Social Science & Medicine, Elsevier, vol. 91(C), pages 122-129.

    Cited by:

    1. Reavey, P. & Brown, S.D. & Kanyeredzi, A. & McGrath, L. & Tucker, I., 2019. "Agents and spectres: Life-space on a medium secure forensic psychiatric unit," Social Science & Medicine, Elsevier, vol. 220(C), pages 273-282.
    2. Wood, Victoria J. & Curtis, Sarah E. & Gesler, Wil & Spencer, Ian H. & Close, Helen J. & Mason, James M. & Reilly, Joe G., 2013. "Spaces for smoking in a psychiatric hospital: Social capital, resistance to control, and significance for ‘therapeutic landscapes’," Social Science & Medicine, Elsevier, vol. 97(C), pages 104-111.
    3. Norvoll, Reidun & Pedersen, Reidar, 2016. "Exploring the views of people with mental health problems' on the concept of coercion: Towards a broader socio-ethical perspective," Social Science & Medicine, Elsevier, vol. 156(C), pages 204-211.
    4. Houghton, Frank & Houghton, Sharon, 2015. "Therapeutic micro-environments in the Edgelands: A thematic analysis of Richard Mabey's The Unofficial Countryside," Social Science & Medicine, Elsevier, vol. 133(C), pages 280-286.
    5. Curtis, Sarah & Gesler, Wilbert & Wood, Victoria & Spencer, Ian & Mason, James & Close, Helen & Reilly, Joseph, 2013. "Compassionate containment? Balancing technical safety and therapy in the design of psychiatric wards," Social Science & Medicine, Elsevier, vol. 97(C), pages 201-209.
    6. Bell, Sarah L. & Foley, Ronan & Houghton, Frank & Maddrell, Avril & Williams, Allison M., 2018. "From therapeutic landscapes to healthy spaces, places and practices: A scoping review," Social Science & Medicine, Elsevier, vol. 196(C), pages 123-130.

  4. Curtis, Sarah & Gesler, Wilbert & Wood, Victoria & Spencer, Ian & Mason, James & Close, Helen & Reilly, Joseph, 2013. "Compassionate containment? Balancing technical safety and therapy in the design of psychiatric wards," Social Science & Medicine, Elsevier, vol. 97(C), pages 201-209.

    Cited by:

    1. Högström, Ebba & Philo, Chris, 2023. "‘Let there be light’ or life in the dark? Vital geographies of mental healthcare," Social Science & Medicine, Elsevier, vol. 333(C).
    2. Reavey, P. & Brown, S.D. & Kanyeredzi, A. & McGrath, L. & Tucker, I., 2019. "Agents and spectres: Life-space on a medium secure forensic psychiatric unit," Social Science & Medicine, Elsevier, vol. 220(C), pages 273-282.
    3. Taheri, Shima & Ghasemi Sichani, Maryam & Shabani, Amirhosein, 2021. "Evaluating the literature of therapeutic landscapes with an emphasis on the search for the dimensions of health: A systematic review," Social Science & Medicine, Elsevier, vol. 275(C).
    4. Melo, Sara, 2018. "The role of place on healthcare quality improvement: A qualitative case study of a teaching hospital," Social Science & Medicine, Elsevier, vol. 202(C), pages 136-142.
    5. Wood, Victoria J. & Curtis, Sarah E. & Gesler, Wil & Spencer, Ian H. & Close, Helen J. & Mason, James M. & Reilly, Joe G., 2013. "Spaces for smoking in a psychiatric hospital: Social capital, resistance to control, and significance for ‘therapeutic landscapes’," Social Science & Medicine, Elsevier, vol. 97(C), pages 104-111.
    6. Jacqueline McIntosh & Bruno Marques & Gabrielle Jenkin, 2022. "The Role of Courtyards within Acute Mental Health Wards: Designing with Recovery in Mind," IJERPH, MDPI, vol. 19(18), pages 1-21, September.

  5. Wood, Victoria J. & Curtis, Sarah E. & Gesler, Wil & Spencer, Ian H. & Close, Helen J. & Mason, James M. & Reilly, Joe G., 2013. "Spaces for smoking in a psychiatric hospital: Social capital, resistance to control, and significance for ‘therapeutic landscapes’," Social Science & Medicine, Elsevier, vol. 97(C), pages 104-111.

    Cited by:

    1. Power, Andrew & Bell, Sarah L. & Kyle, Richard G. & Andrews, Gavin J., 2019. "‘Hopeful adaptation’ in health geographies: Seeking health and wellbeing in times of adversity," Social Science & Medicine, Elsevier, vol. 231(C), pages 1-5.
    2. Houghton, Frank & Houghton, Sharon, 2015. "Therapeutic micro-environments in the Edgelands: A thematic analysis of Richard Mabey's The Unofficial Countryside," Social Science & Medicine, Elsevier, vol. 133(C), pages 280-286.
    3. Curtis, Sarah & Gesler, Wilbert & Wood, Victoria & Spencer, Ian & Mason, James & Close, Helen & Reilly, Joseph, 2013. "Compassionate containment? Balancing technical safety and therapy in the design of psychiatric wards," Social Science & Medicine, Elsevier, vol. 97(C), pages 201-209.
    4. Bell, Sarah L. & Foley, Ronan & Houghton, Frank & Maddrell, Avril & Williams, Allison M., 2018. "From therapeutic landscapes to healthy spaces, places and practices: A scoping review," Social Science & Medicine, Elsevier, vol. 196(C), pages 123-130.

  6. Mason, James & Eccles, Martin & Freemantle, Nick & Drummond, Michael, 1999. "A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines," Health Policy, Elsevier, vol. 47(1), pages 37-52, April.

    Cited by:

    1. Andrea Anonychuk & Andrea Tricco & Chris Bauch & Ba’ Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn, 2008. "Cost-Effectiveness Analyses of Hepatitis A Vaccine," PharmacoEconomics, Springer, vol. 26(1), pages 17-32, January.
    2. Van Herten, Loes M. & Gunning-Shepers, Louise J., 2000. "Targets as a tool in health policy. Part II: guidelines for application," Health Policy, Elsevier, vol. 53(1), pages 13-23, August.
    3. van Os, Nicole & Niessen, Louis W. & Bilo, Henk J. G. & Casparie, Anton F. & van Hout, Ben A., 2000. "Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines," Health Policy, Elsevier, vol. 51(3), pages 135-147, April.

  7. Mason, James & Drummond, Michael, 1997. "Biotechnology: a special case for health technology assessment?," Health Policy, Elsevier, vol. 41(1), pages 73-81, July.

    Cited by:

    1. Freemantle, Nick, 1999. "Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?," Health Policy, Elsevier, vol. 46(3), pages 255-265, March.
    2. Rogowski, Wolf, 2007. "Current impact of gene technology on healthcare: A map of economic assessments," Health Policy, Elsevier, vol. 80(2), pages 340-357, February.

  8. James Mason & Michael Drummond, 1995. "Reporting guidelines for economic studies," Health Economics, John Wiley & Sons, Ltd., vol. 4(2), pages 85-94, March.

    Cited by:

    1. Tom Jefferson & Miranda Mugford & Alastair Gray & Vittorio Demicheli, 1996. "An exercise on the feasibility of carrying out secondary economic analyses," Health Economics, John Wiley & Sons, Ltd., vol. 5(2), pages 155-165, March.
    2. Anna García‐Altés, 2001. "Twenty years of health care economic analysis in Spain: are we doing well?," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 715-729, December.
    3. Mark Schreiner, 2001. "Evaluation and Microenterprise Programs," Development and Comp Systems 0108002, University Library of Munich, Germany, revised 27 Dec 2001.
    4. Trevor A. Sheldon, 1996. "Problems of using modelling in the economic evaluation of health care," Health Economics, John Wiley & Sons, Ltd., vol. 5(1), pages 1-11, January.
    5. Chaim M. Bell & Richard H. Chapman & Patricia W. Stone & Eileen A. Sandberg & Peter J. Neumann, 2001. "An Off-the-Shelf Help List," Medical Decision Making, , vol. 21(4), pages 288-294, August.
    6. Lindholm, Lars & Hallgren, C. -G. & Boman, Kurt & Markgren, Kenth & Weinehall, Lars & Ogren, J. -E., 1999. "Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?," Health Policy, Elsevier, vol. 48(3), pages 155-170, August.
    7. Nancy Wolff & Thomas W. Helminiak, 1996. "Nonsampling measurement error in administrative data: Implications for economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 5(6), pages 501-512, November.
    8. James Mason & Martin Eccles & Nick Freemantle & Mike Drummond, 1998. "NICEly does it: economic analysis within evidence-based clinical practice guidelines," Working Papers 164chedp, Centre for Health Economics, University of York.
    9. Christopher J.L. Murray & David B. Evans & Arnab Acharya & Rob M.P.M. Baltussen, 2000. "Development of WHO guidelines on generalized cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 9(3), pages 235-251, April.
    10. Gerard, Karen & Smoker, Irenie & Seymour, Janelle, 1999. "Raising the quality of cost-utility analyses: lessons learnt and still to learn," Health Policy, Elsevier, vol. 46(3), pages 217-238, March.

  9. Drummond, Michael & Mason, James & Torrance, George, 1995. "Cost-effectiveness league tables: think of the fans," Health Policy, Elsevier, vol. 31(3), pages 231-238, March.

    Cited by:

    1. Keith Tolley;Gareth Morgan;Ray Cartwright;Rhys Williams, 1998. "Economic Aspects of Non-Hodgkin's Lymphoma," Series on Health 000436, Office of Health Economics.
    2. Leonie Segal & Kim Dalziel & Duncan Mortimer, 2010. "Fixing the game: are between‐silo differences in funding arrangements handicapping some interventions and giving others a head‐start?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 449-465, April.
    3. Christopher J.L. Murray & David B. Evans & Arnab Acharya & Rob M.P.M. Baltussen, 2000. "Development of WHO guidelines on generalized cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 9(3), pages 235-251, April.
    4. A. David Paltiel & Kenneth A. Freedberg, 1998. "The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients," Interfaces, INFORMS, vol. 28(3), pages 34-51, June.

  10. Drummond, Michael & Torrance, George & Mason, James, 1993. "Cost-effectiveness league tables: More harm than good?," Social Science & Medicine, Elsevier, vol. 37(1), pages 33-40, July.

    Cited by:

    1. Tom Jefferson & Miranda Mugford & Alastair Gray & Vittorio Demicheli, 1996. "An exercise on the feasibility of carrying out secondary economic analyses," Health Economics, John Wiley & Sons, Ltd., vol. 5(2), pages 155-165, March.
    2. James Mason & Mike Drummond, 1995. "The DH register of cost-effectiveness studies: a review of study content and quality," Working Papers 128chedp, Centre for Health Economics, University of York.
    3. Debby Postulart & Eddy M.M. Adang, 2000. "Response Shift and Adaptation in Chronically III Patients," Medical Decision Making, , vol. 20(2), pages 186-193, April.
    4. Raymond C.W. Hutubessy & Rob M.P.M. Baltussen & David B. Evans & Jan J. Barendregt & Christopher J.L. Murray, 2001. "Stochastic league tables: communicating cost‐effectiveness results to decision‐makers," Health Economics, John Wiley & Sons, Ltd., vol. 10(5), pages 473-477, July.
    5. A. David Paltiel & Julie A. Scharfstein & George R. Seage & Elena Losina & Sue J. Goldie & Milton C. Weinstein & Donald E. Craven & Kenneth A. Freedberg, 1998. "A Monte Carlo Simulation of Advanced HIV Disease," Medical Decision Making, , vol. 18(2_suppl), pages 93-105, April.
    6. Tappenden, P & Brazier, J & Ratcliffe, J, 2006. "Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A," MPRA Paper 29772, University Library of Munich, Germany.
    7. Rutten, Frans, 1996. "Economic evaluation and health care decision-making," Health Policy, Elsevier, vol. 36(3), pages 215-229, June.
    8. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
    9. Richard H. Chapman & Patricia W. Stone & Eileen A. Sandberg & Chaim Bell & Peter J. Neumann, 2000. "A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies," Medical Decision Making, , vol. 20(4), pages 451-458, October.
    10. Coast, Joanna, 2018. "A history that goes hand in hand: Reflections on the development of health economics and the role played by Social Science & Medicine, 1967–2017," Social Science & Medicine, Elsevier, vol. 196(C), pages 227-232.
    11. Phusit Prakongsai & Natasha Palmer & Preecha Uay-Trakul & Viroj Tangcharoensathien & Anne Mills, 2009. "The implications of benefit package design: the impact on poor Thai households of excluding renal replacement therapy," Journal of International Development, John Wiley & Sons, Ltd., vol. 21(2), pages 291-308.
    12. Joakim Ramsberg, 2002. "When should expenditure per life saved vary?," Journal of Risk Research, Taylor & Francis Journals, vol. 5(3), pages 249-263, July.
    13. Gafni, Amiram & Birch, Stephen, 2006. "Incremental cost-effectiveness ratios (ICERs): The silence of the lambda," Social Science & Medicine, Elsevier, vol. 62(9), pages 2091-2100, May.
    14. Peter J. Neumann & Darren E. Zinner & Janice C. Wright, 1997. "Are Methods for Estimating QALYs in Cost-Effectiveness Analyses Improving?," Medical Decision Making, , vol. 17(4), pages 402-408, October.
    15. Wolfgang C. Winkelmayer & Milton C. Weinstein & Murray A. Mittleman & Robert J. Glynn & Joseph S. Pliskin, 2002. "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making, , vol. 22(5), pages 417-430, October.
    16. Christopher J.L. Murray & David B. Evans & Arnab Acharya & Rob M.P.M. Baltussen, 2000. "Development of WHO guidelines on generalized cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 9(3), pages 235-251, April.
    17. Lindholm, Lars & Rosen, Mans & Emmelin, Maria, 1996. "An epidemiological approach towards measuring the trade-off between equity and efficiency in health policy," Health Policy, Elsevier, vol. 35(3), pages 205-216, March.
    18. Cookson, Richard & Hutton, John, 2003. "Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective," Health Policy, Elsevier, vol. 63(2), pages 167-178, February.
    19. Ann E. Clarke, 1997. "Arthritis Patient Education: How Economic Evaluations Can Inform Health Policy," Canadian Public Policy, University of Toronto Press, vol. 23(s1), pages 162-176, Spring.
    20. Andrew R. Willan & Bernie J. O'Brien, 1996. "Confidence intervals for cost‐effectiveness ratios: An application of Fieller's theorem," Health Economics, John Wiley & Sons, Ltd., vol. 5(4), pages 297-305, July.
    21. Drummond, Michael & Mason, James & Torrance, George, 1995. "Cost-effectiveness league tables: think of the fans," Health Policy, Elsevier, vol. 31(3), pages 231-238, March.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, James Mason should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.